Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia

Published:1997-01 Issue:3-4 Volume:25 Page:365-372
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

De La Sernas Javier,Tomás Jose Francisco,Solano Carlos,García De Paredes Maria Luisa,Campbell Joaquín,Grande Carlos,Diaz-Mediavilla Joaquín

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199709114175

Reference32 articles.

1. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients

2. Varying intensity of postremission therapy in acute myeloid leukemia

3. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia [see comments]

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consolidation in AML: Abundant opinion and much unknown;Blood Reviews;2022-01

2. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

3. A New Chemiluminescence Method for Determination of Cytosine Arabinoside in Pharmaceutical Preparations;Bulletin of the Korean Chemical Society;2012-01-20

4. Aktuelle Therapiestrategien in der Behandlung der akuten myeloischen Leukämie;Medizinische Klinik;2007-04

5. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia;Leukemia Research;2006-02